STOCK TITAN

JATT III Acquisition: Great Point reports 5.08% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

JATT III Acquisition Corp (JTTT) reports that Great Point Partners, LLC, its Senior Managing Member Dr. Jeffrey R. Jay, M.D., and its Managing Director Ms. Lillian Nordahl each report beneficial ownership of 450,000 common shares, or 5.08%, with shared voting and dispositive power as of September 30, 2026. These are overlapping reports of the same shares, not three separate blocks.

Biomedical Value Fund, L.P. holds 297,000 shares of record and Biomedical Offshore Value Fund, Ltd. holds 153,000; Great Point Partners is the investment manager of both funds. The reporting persons disclaim beneficial ownership except to the extent of their respective pecuniary interests. The percentage is based on 8,859,000 shares outstanding, as reported in a prospectus filed August 26, 2026.

Common shares beneficially owned 450,000 shares Each reporting person reports the same shared position as of September 30, 2026.
Percent of class 5.08% Reported by each reporting person; based on 8,859,000 shares outstanding.
Shares outstanding 8,859,000 shares Reported by the issuer in a prospectus filed August 26, 2026.
BVF shares held of record 297,000 shares Biomedical Value Fund, L.P.
BOVF shares held of record 153,000 shares Biomedical Offshore Value Fund, Ltd.
beneficial ownership financial
"Aggregate Amount Beneficially Owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power regulatory
"Shared Voting Power 450,000"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 450,000"
pecuniary interests financial
"except to the extent of their respective pecuniary interests"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many JTTT shares did the reporting persons report owning?

Each of the three reporting persons reported beneficial ownership of 450,000 common shares, or 5.08%, as of September 30, 2026. Their reports refer to the same shares, with shared voting and dispositive power.

Which funds hold the JTTT shares reported by Great Point Partners?

Biomedical Value Fund, L.P. holds 297,000 shares of record, and Biomedical Offshore Value Fund, Ltd. holds 153,000 shares of record. Great Point Partners is the investment manager of both funds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





G5080G109

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Great Point Partners, LLC
Signature:/s/ Dr. Jeffrey R. Jay, M.D
Name/Title:Dr. Jeffrey R. Jay, M.D - Senior Managing Member
Date:11/16/2026
Dr. Jeffrey R. Jay, M.D.
Signature:/s/ Dr. Jeffrey R. Jay, M.D
Name/Title:Dr. Jeffrey R. Jay, M.D
Date:11/16/2026
Ms. Lillian Nordahl
Signature:/s/ Ms. Lillian Nordahl
Name/Title:Ms. Lillian Nordahl
Date:11/16/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the SCHEDULE 13G to which this Exhibit is attached, and such SCHEDULE 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such SCHEDULE 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Dated: November 16, 2026 Great Point Partners, LLC By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D., as Senior Managing Member Dr. Jeffrey R. Jay, M.D. By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl By: /s/ Ms. Lillian Nordahl Ms. Lillian Nordahl

Keep reading